ES2095043T3 - Composicion para preparados orales. - Google Patents

Composicion para preparados orales.

Info

Publication number
ES2095043T3
ES2095043T3 ES93905625T ES93905625T ES2095043T3 ES 2095043 T3 ES2095043 T3 ES 2095043T3 ES 93905625 T ES93905625 T ES 93905625T ES 93905625 T ES93905625 T ES 93905625T ES 2095043 T3 ES2095043 T3 ES 2095043T3
Authority
ES
Spain
Prior art keywords
composition
oral preparations
basic
weight based
unpleasant flavor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93905625T
Other languages
English (en)
Inventor
Toshio Yajima
Kuniaki Ishii
Nobuo Umeki
Shigeru Itai
Hidefumi Hayashi
Kimihide Shimano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2095043T3 publication Critical patent/ES2095043T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

SE PRESENTA UNA COMPOSICION PARA PREPARACIONES ORALES QUE CONSTA DE UN COMPLEJO FORMADO MEDIANTE LA DISPERSION O LA DISOLUCION DE UN MEDICAMENTO BASICO DE SABOR DESAGRADABLE Y UN COMPUESTO DE POLIMERO DE FUNCION EN UNA SUSTANCIA QUE TIENE UN PUNTO DE FUSION BAJO, DEL 10 AL 70% EN PESO BASADO EN LA COMPOSICION DE ALCOHOL DE AZUCAR Y DE UN 0.1 A UN 7% EN PESO BASADO EN LA COMPOSICION DE UN OXIDO BASICO. LA COMPOSICION ES EXCELENTE PARA PREPARACIONES ORALES, PARA EL MASTICADO DE MEDICAMENTOS BASICOS DE SABOR DESAGRADABLE Y TIENE UN COMPORTAMIENTO EXCELENTE PARA USO BIOLOGICO.
ES93905625T 1992-03-12 1993-03-10 Composicion para preparados orales. Expired - Lifetime ES2095043T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5344292 1992-03-12
JP21990492 1992-08-19

Publications (1)

Publication Number Publication Date
ES2095043T3 true ES2095043T3 (es) 1997-02-01

Family

ID=26394153

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93905625T Expired - Lifetime ES2095043T3 (es) 1992-03-12 1993-03-10 Composicion para preparados orales.

Country Status (12)

Country Link
US (1) US5707646A (es)
EP (1) EP0630233B1 (es)
JP (1) JP3265680B2 (es)
AT (1) ATE143258T1 (es)
AU (1) AU670428B2 (es)
CA (1) CA2131547C (es)
DE (1) DE69305069T2 (es)
ES (1) ES2095043T3 (es)
FI (1) FI109657B (es)
MX (1) MXPA93001352A (es)
NO (1) NO308022B1 (es)
WO (1) WO1993017667A1 (es)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0168715B1 (ko) * 1992-11-30 1999-01-15 밋첼 아이. 커시너 맛을 차단하는 약제학적 조성물
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE69530973T2 (de) * 1994-02-16 2004-05-19 Abbott Laboratories, Abbott Park Verfahren zur herstellung feinteiliger pharmazeutischer formulierungen
US5728403A (en) * 1994-10-05 1998-03-17 The Board Of Regents Of The University Of Nebraska Coating technology for taste masking orally administered bitter drugs
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE29502547U1 (de) * 1995-02-16 1995-03-30 Röhm GmbH, 64293 Darmstadt Thermoplastisches Überzugs- und Bindemittel für Arzneiformen
CA2219991C (en) * 1995-05-02 2007-10-30 Taisho Pharmaceutical Co., Ltd. Taste masking pharmaceutical composition for oral administration
AUPO637197A0 (en) * 1997-04-23 1997-05-15 F.H. Faulding & Co. Limited Taste-masked pharmaceutical compositions
DE19617487A1 (de) † 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
DE19706978A1 (de) * 1997-02-21 1998-08-27 Ulrich Dr Posanski Kombinationspräparat für oral applizierbare Antibiotika
DE19706979A1 (de) * 1997-02-21 1998-08-27 Lindopharm Gmbh Kombinationspräparat für oral applizierbare Erythromycine
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6861411B1 (en) * 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
JP3466921B2 (ja) * 1998-06-03 2003-11-17 大塚製薬株式会社 味マスキング医薬製剤
WO2000018372A1 (fr) * 1998-09-30 2000-04-06 Taisho Pharmaceutical Co., Ltd. Granules pour preparations orales
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
HK1044476B (zh) * 1999-03-17 2010-09-17 第一制药株式会社 药物组合物
SI20244A (sl) * 1999-05-19 2000-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Granulacija v talini
IN191239B (es) 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
ATE432691T1 (de) * 2000-03-28 2009-06-15 Sandoz Ag Geschmackmaskierte granulierte teilchen
PT1276470E (pt) 2000-04-20 2007-08-13 Novartis Ag Composição de revestimento para dissimular o sabor
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
WO2001091730A1 (en) 2000-05-31 2001-12-06 Drugtech Corporation Mineral supplement
WO2001091761A1 (fr) * 2000-06-01 2001-12-06 Taisho Pharmaceutical Co.,Ltd. Matrices pour preparations orales
KR100863146B1 (ko) * 2000-07-17 2008-10-14 아스텔라스세이야쿠 가부시키가이샤 경구 흡수 개선 의약 조성물
EP1319399A1 (en) * 2000-09-19 2003-06-18 Daiichi Pharmaceutical Co., Ltd. Medicinal composition
US7510728B2 (en) 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
MXPA03003146A (es) * 2000-10-13 2004-12-06 Advancis Pharmaceuticals Derivados de eritromicina de liberacion prolongada.
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
JP4706096B2 (ja) * 2000-10-23 2011-06-22 大正製薬株式会社 不快な味を呈する塩基性薬物配合製剤
WO2002041887A1 (en) * 2000-11-21 2002-05-30 Kyorin Pharmaceutical Co., Ltd. Dry syrup preparations
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AU2002327418A1 (en) * 2001-08-01 2003-02-17 Bristol-Myers Squibb Company Taste masking composition
BR0307332A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US20040043073A1 (en) * 2002-06-14 2004-03-04 Chih-Ming Chen Pharmaceutical compositions for drugs having pH-dependent solubility
CN1681479A (zh) 2002-08-12 2005-10-12 辉瑞产品公司 半有序药物和聚合物的药物组合物
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040146553A1 (en) * 2002-12-23 2004-07-29 Aventis Pharma S.A. Compositions for oral administration of active principles requiring masking of taste
KR100508992B1 (ko) * 2003-03-31 2005-08-17 한국유나이티드제약 주식회사 쓴 맛을 개선한 클래리스로마이신 경구용 약제 조성물 및 그의 제조 방법
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
EP1663169A4 (en) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In ANTIBIOTICS, ITS USE AND FORMULATION
US20080293801A1 (en) * 2003-11-14 2008-11-27 Pfizer Inc. Solid Amorphous Dispersions of An Mtp Inhibitor For Treatment of Obesity
JP2007513147A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
WO2005053651A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
BRPI0416535A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
RU2331410C2 (ru) * 2003-12-04 2008-08-20 Пфайзер Продактс Инк. Способ получения фармацевтических мультичастиц
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
BRPI0417338A (pt) * 2003-12-04 2007-04-17 Pfizer Prod Inc formas de dosagem de azitromicina multiparticulada por processos a base de lìquido
BRPI0417492A (pt) * 2003-12-09 2007-05-29 Pfizer composições compreendendo um inibidor de protease de hiv
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
US8420115B2 (en) 2004-06-03 2013-04-16 Taisho Pharmaceutical Co., Ltd. Oral preparations and process for production thereof
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
WO2009085637A1 (en) * 2007-12-21 2009-07-09 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
PL2280704T3 (pl) * 2008-03-31 2015-10-30 Cymabay Therapeutics Inc Związki oksymetylenoarylowe i ich zastosowania
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
DE102009019268A1 (de) * 2009-04-28 2010-11-11 Lts Lohmann Therapie-Systeme Ag Arzneimittel mit poröser Matrix
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011145022A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
BR112012032248A2 (pt) 2010-06-23 2016-09-13 Metabolex Inc composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
CU24395B1 (es) 2014-03-17 2019-04-04 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
US9867809B2 (en) 2015-06-30 2018-01-16 Kemin Industries, Inc. Encapsulated active ingredients for controlled enteric release
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
SG10202110112TA (en) 2017-03-10 2021-10-28 Pfizer Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
JP7161605B2 (ja) 2018-08-31 2022-10-26 ファイザー・インク Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ
AU2020260018A1 (en) 2019-04-19 2021-11-04 Pfizer Inc. Anti-proliferative agents for treating PAH
CA3140972C (en) 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
JP7498199B2 (ja) 2019-06-28 2024-06-11 ファイザー・インク 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
CN115209876A (zh) * 2020-03-11 2022-10-18 泽井制药株式会社 颗粒和使用该颗粒的制剂
LT4161927T (lt) 2020-06-09 2024-09-25 Pfizer Inc. Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas
IL312296A (en) 2021-12-01 2024-06-01 Pfizer 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART
WO2023105387A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
AU2023358062A1 (en) 2022-10-07 2025-03-20 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
US12637461B2 (en) 2022-10-18 2026-05-26 Pfizer Inc. Compounds for the activation of AMPK
IL319392A (en) 2022-10-18 2025-05-01 Pfizer Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations
EP4604955A1 (en) 2022-10-18 2025-08-27 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000254A (en) * 1966-04-25 1976-12-28 Schmid Laboratories, Inc. Fungimycin compositions
US3627885A (en) * 1968-07-18 1971-12-14 Rit Rech Ind Therapeut Stabilized antibiotic compositions for animal feeding
US3857939A (en) * 1971-08-18 1974-12-31 Hoffmann La Roche Chewable sodium-free vitamin c tablets
US3865935A (en) * 1972-08-10 1975-02-11 Abbott Lab Tableting of erythromycin base
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
SE8203953D0 (sv) * 1982-06-24 1982-06-24 Astra Laekemedel Ab Pharmaceutical mixture
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US5271946A (en) * 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
US4925675A (en) * 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
CA2031206A1 (en) * 1989-04-18 1990-10-19 Ikuo Koyama Process for producing flavored pharmaceutical preparation for oral administration
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
KR0168715B1 (ko) * 1992-11-30 1999-01-15 밋첼 아이. 커시너 맛을 차단하는 약제학적 조성물

Also Published As

Publication number Publication date
US5707646A (en) 1998-01-13
CA2131547C (en) 2002-02-12
FI944165L (fi) 1994-09-09
EP0630233B1 (en) 1996-09-25
AU3648493A (en) 1993-10-05
MXPA93001352A (es) 2005-02-22
WO1993017667A1 (en) 1993-09-16
NO943341D0 (no) 1994-09-09
FI109657B (fi) 2002-09-30
ATE143258T1 (de) 1996-10-15
DE69305069T2 (de) 1997-03-13
EP0630233A1 (en) 1994-12-28
CA2131547A1 (en) 1993-09-16
FI944165A0 (fi) 1994-09-09
DE69305069D1 (de) 1996-10-31
NO943341L (no) 1994-09-09
JPH06116138A (ja) 1994-04-26
NO308022B1 (no) 2000-07-10
JP3265680B2 (ja) 2002-03-11
AU670428B2 (en) 1996-07-18

Similar Documents

Publication Publication Date Title
ATE79619T1 (de) Arzneimittel.
ES488168A0 (es) Proceso para la preparacion de tabletas farmaceuticas o medicinales de administracion oral, con liberacion retardada delagente activo, en tabletas en las que la cantidad de libera-cion del agente activo es predeterminada.
IT8719064A0 (it) Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive.
ES2083197T3 (es) Gel cosmetico acuoso de bajo ph que contiene derivados de poliacrilamida no ionica.
ATE143830T1 (de) Mikrokapseln mit wänden aus primären alkoholfunktionen enthaltenden polysacchariden, und zusammensetzungen daraus
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
DE69521693D1 (de) Taxanderivate enthaltende arzneizubereitungen
SE8700498D0 (sv) Novel pharmaceologically active compounds
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
FR2679906B1 (fr) Nouvelles (isoquinolein-5 yl) sulfonamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AR009231A1 (es) Formulaciones en aerosol de formoterol.
AR224323A1 (es) Composicion insecticida sinergizada que contiene crisantemato de n-(3,4,5,6-terahidroftalimido)-metilo o de 2-ali-3-metil-ciclopent-2-en-1-on-4-ilo y 3-fenoxibencil-2',2'-dimetil-3'-(2",2"-diclorovinil)-ciclopropanocarboxilato
BR0005549A (pt) Ampola para o acondicionamento de um lìquido de uso médico
ATE186212T1 (de) Geschmacksmaskierte pharmazeutische mittel
DE3583916D1 (de) Waessrige arzneiformulierungen des piroxicammonohydrats.
DK157689A (da) Farmaceutiske piroxicammidler i vandige oploesninger samt fremgangsmaade til fremstilling heraf
FI792884A7 (fi) Fenyylialkyyliaminoetyylisalisyyliamidi, sen valmistus ja sitä sisältävät farmaseuttiset seokset.
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
ATE107853T1 (de) Orales, melatonin enthaltendes arzneimittel.
DK0460622T3 (da) Lægemiddelpræparat til systemisk behandling af pryd- og nyttefisk
ES2171459T3 (es) Polvo para administracion nasal de farmaco peptidico o proteinaceo.
DE69530380D1 (de) Retropeptide, antikörper dagegen und deren verwendungen in der impfung und in vitro diagnostik
DE68900152D1 (de) Acetylcystein enthaltendes, festes, wasserloeslisches arzneimittel.
FI803704A7 (fi) Heterosyklinen yhdiste ja sen synteesi, sitä sisältävät farmaseuttiset koostumukset ja yhdisteiden ja koostumukoostumusten käyttö lääketieteessä.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 630233

Country of ref document: ES